|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Horeweg N, van Rosmalen J, Heuvelmans MA,
van der Aalst CM, Vliegenthart R, Scholten ET, ten Haaf K,
Nackaerts K, Lammers JW, Weenink C, et al: Lung cancer probability
in patients with CT-detected pulmonary nodules: A prespecified
analysis of data from the NELSON trial of low-dose CT screening.
Lancet Oncol. 15:1332–1341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cedolini C, Bertozzi S, Londero AP,
Bernardi S, Seriau L, Concina S, Cattin F and Risaliti A: Type of
breast cancer diagnosis, screening, and survival. Clin Breast
Cancer. 14:235–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Board PDQATE. Non-small cell lung cancer
treatment (PDQ(R)), . Health professional version. PDQ cancer
information summaries Bethesda (MD): National Cancer Institute
(US); 2002
|
|
6
|
Yatabe Y, Dacic S, Borczuk AC, Warth A,
Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G,
Rekhtman N, et al: Best practices recommendations for diagnostic
immunohistochemistry in lung cancer. J Thorac Oncol. 14:377–407.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin CK, Hsu YT, Christiani DC, Hung HY and
Lin RT: Risks and burden of lung cancer incidence for residential
petrochemical industrial complexes: A meta-analysis and
application. Environ Int. 121:404–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shukuya T and Carbone DP: Predictive
markers for the efficacy of Anti-PD-1/PD-L1 antibodies in lung
cancer. J Thorac Oncol. 11:976–988. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gettinger S, Rizvi NA, Chow LQ, Borghaei
H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman
JW, et al: Nivolumab monotherapy for First-line treatment of
advanced non-small-cell lung cancer. J Clin Oncol. 34:2980–2987.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xia L, Liu Y and Wang Y: PD-1/PD-L1
blockade therapy in advanced non-small-cell lung cancer: Current
status and future directions. Oncologist. 24 (Suppl 1):S31–S41.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reveiz L, Rueda JR and Cardona AF:
Palliative endobronchial brachytherapy for non-small cell lung
cancer. Cochrane Database Syst Rev. 12:CD0042842012.PubMed/NCBI
|
|
13
|
Li W, Dan G, Jiang J, Zheng Y, Zheng X and
Deng D: Repeated iodine-125 seed implantations combined with
external beam radiotherapy for the treatment of locally recurrent
or metastatic stage III/IV non-small cell lung cancer: A
retrospective study. Radiat Oncol. 11:1192016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Woodard GA, Jones KD and Jablons DM: Lung
cancer staging and prognosis. Cancer Treat Res. 170:47–75. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen BJ, Chapuy B, Ouyang J, Sun HH,
Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA and Rodig
SJ: PD-L1 expression is characteristic of a subset of aggressive
B-cell lymphomas and virus-associated malignancies. Clin Cancer
Res. 19:3462–3473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nkomozepi P, Mazengenya P and Ihunwo AO:
Age-related changes in Ki-67 and DCX expression in the BALB/c mouse
(Mus Musculus) brain. Int J Dev Neurosci. 72:36–47. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World health organization
classification of lung tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meng FJ, Wang S, Zhang J, Yan YJ, Wang CY,
Yang CR, Guan ZY and Wang CL: Alteration in gene expression
profiles of thymoma: Genetic differences and potential novel
targets. Thorac Cancer. 10:1129–1135. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu W, Li Z, Xiong L, Yu X, Chen X and Lin
Q: FKBP3 promotes proliferation of non-small cell lung cancer cells
through regulating Sp1/HDAC2/p27. Theranostics. 7:3078–3089. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu G, Liu Z, Yan Y and Wang H: Effect of
fraxetin on proliferation and apoptosis in breast cancer cells.
Oncol Lett. 14:7374–738. 2017.PubMed/NCBI
|
|
22
|
Abbastabar M, Kheyrollah M, Azizian K,
Bagherlou N, Tehrani SS, Maniati M and Karimian A: Multiple
functions of p27 in cell cycle, apoptosis, epigenetic modification
and transcriptional regulation for the control of cell growth: A
double-edged sword protein. DNA Repair (Amst). 69:63–72. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schafer KA: The cell cycle: A review. Vet
Pathol. 35:461–478. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pham DH, Kim JS, Kim SK, Shin DJ, Uong NT,
Hyun H, Yoon MS, Kang SJ, Ryu YJ, Cho J, et al: Effects of ADAM10
and ADAM17 inhibitors on natural killer cell expansion and
antibody-dependent cellular cytotoxicity against breast cancer
cells in vitro. Anticancer Res. 37:5507–5513. 2017.PubMed/NCBI
|
|
25
|
Bradbury P, Sivajohanathan D, Chan A,
Kulkarni S, Ung Y and Ellis PM: Postoperative adjuvant systemic
therapy in completely resected non-small-cell lung cancer: A
systematic review. Clin Lung Cancer. 18:259–273.e8. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
National Lung Screening Trial Research
Team, ; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD,
Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM and Sicks JD:
Reduced lung-cancer mortality with low-dose computed tomographic
screening. N Engl J Med. 365:395–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sgambato A, Casaluce F, Sacco PC,
Palazzolo G, Maione P, Rossi A, Ciardiello F and Gridelli C: Anti
PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non-small
cell lung cancer (NSCLC): A review on toxicity profile and its
management. Curr Drug Saf. 11:62–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hautmann AH, Hautmann MG, Kölbl O, Herr W
and Fleck M: Tumor-induced osteomalacia: An up-to-date review. Curr
Rheumatol Rep. 17:5122015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weber J: Immune checkpoint proteins: A new
therapeutic paradigm for cancer-preclinical background: CTLA-4 and
PD-1 blockade. Semin Oncol. 37:430–439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Şahin S, Batur Ş, Aydın Ö, Öztürk T, Turna
A and Öz B: Programmed death-ligand-1 expression in non small cell
lung cancer and prognosis. Balkan Med J. 36:184–189. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Velcheti V, Schalper KA, Carvajal DE,
Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L
and Rimm DL: Programmed death ligand-1 expression in non-small cell
lung cancer. Lab Invest. 94:107–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Horn L, Mansfield AS, Szczęsna A, Havel L,
Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio
M, et al: First-line atezolizumab plus chemotherapy in
extensive-stage small-cell lung cancer. N Engl J Med.
379:2220–2229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Q and Wu X: Primary and acquired
resistance to PD-1/PD-L1 blockade in cancer treatment. Int
Immunopharmacol. 46:210–219. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thompson ED, Taube JM, Asch-Kendrick RJ,
Ogurtsova A, Xu H, Sharma R, Meeker A, Argani P, Emens LA,
Cimino-Mathews A, et al: PD-L1 expression and the immune
microenvironment in primary invasive lobular carcinomas of the
breast. Mod Pathol. 30:1551–1560. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mullooly M, McGowan PM, Crown J and Duffy
MJ: The ADAMs family of proteases as targets for the treatment of
cancer. Cancer Biol Ther. 17:870–880. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng
P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et
al: Blockade of B7-H1 improves myeloid dendritic cell-mediated
antitumor immunity. Nat Med. 9:562–567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Francisco LM, Salinas VH, Brown KE,
Vanguri VK, Freeman GJ, Kuchroo VK and Sharpe AH: PD-L1 regulates
the development, maintenance, and function of induced regulatory T
cells. J Exp Med. 206:3015–329. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Thompson RH, Gillett MD, Cheville JC,
Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen
L, et al: Costimulatory B7-H1 in renal cell carcinoma patients:
Indicator of tumor aggressiveness and potential therapeutic target.
Proc Natl Acad Sci USA. 101:17174–1779. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Haanen JB and Robert C: Immune checkpoint
inhibitors. Prog Tumor Res. 42:55–66. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Izzedine H, Mateus C, Boutros C, Robert C,
Rouvier P, Amoura Z and Mathian A: Renal effects of immune
checkpoint inhibitors. Nephrol Dial Transplant. 32:936–942.
2017.PubMed/NCBI
|
|
42
|
Doroshow DB, Sanmamed MF, Hastings K,
Politi K, Rimm DL, Chen L, Melero I, Schalper KA and Herbst RS:
Immunotherapy in non-small cell lung cancer: Facts and hopes. Clin
Cancer Res. 25:4592–4602. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Caccese M, Indraccolo S, Zagonel V and
Lombardi G: PD-1/PD-L1 immune-checkpoint inhibitors in
glioblastoma: A concise review. Crit Rev Oncol Hematol.
135:128–134. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rossello A, Nuti E, Ferrini S and Fabbi M:
Targeting ADAM17 sheddase activity in cancer. Curr Drug Targets.
17:1908–1927. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Moss ML and Minond D: Recent advances in
ADAM17 research: A promising target for cancer and inflammation.
Mediators Inflamm. 2017:96735372017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Buchanan PC, Boylan KLM, Walcheck B,
Heinze R, Geller MA, Argenta PA and Skubitz APN: Ectodomain
shedding of the cell adhesion molecule Nectin-4 in ovarian cancer
is mediated by ADAM10 and ADAM17. J Biol Chem. 292:6339–6351. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wu J, Mishra HK and Walcheck B: Role of
ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a
potential target for cancer immunotherapy. J Leukoc Biol.
105:1297–1303. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang R, Li Y, Tsung A, Huang H, Du Q, Yang
M, Deng M, Xiong S, Wang X, Zhang L, et al: iNOS promotes
CD24+CD133+ liver cancer stem cell phenotype
through a TACE/ADAM17-dependent Notch signaling pathway. Proc Natl
Acad Sci USA. 115:E10127–E10136. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lan T, Wang H, Zhang Z, Zhang M, Qu Y,
Zhao Z, Fan X, Zhan Q, Song Y and Yu C: Downregulation of
β-arrestin 1 suppresses glioblastoma cell malignant progression vis
inhibition of Src signaling. Exp Cell Res. 357:51–58. 2017.
View Article : Google Scholar : PubMed/NCBI
|
